Expertise and advice on analysing real-world data

Harnessing real-world data to enlarge medical knowledge and address quality of care
illustration-expertise-conseil
Expertise

Effective tools for healthcare professionals

pelyon-accueil-image-expertise
pelyon-accueil-icon-etudes-epidemiologiques

Epidemiological studies

pelyon-accueil-icon-etudes-pharmaco-epidemiologiques

Pharmacoepidemiological studies

pelyon-accueil-icon-evaluations

Assessment

pelyon-accueil-icon-etudes-economiques

Economic studies

pelyon-accueil-icon-assistance-conseil

Methodological assistance and advice

Application fields

pelyon-accueil-icon-qualite-soins
Quality of care
pelyon-accueil-icon-usage-medicament
Therapeutic adherence
pelyon-accueil-icon-adhesion
Drug use
pelyon-accueil-icon-etudes-cout-maladie
Cost of illness study
pelyon-accueil-icon-prise-en-charge
Comparison of treatment strategies

News

SNDS: What is it and why using it?

21/02/2023
Please find below a publication from PELyon on LinkedIn about the possibilities offered by the SNDS and the ESND in terms of Real World Evidence. Do not hesitate to contact us to determine how these databases can fulfill your needs and what are the best options for your upcoming RWE…

New Article

28/11/2022
We are pleased to share our new article written in collaboration with the Hospices Civils de Lyon: Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France, published in Frontiers in Public Health.

PELyon has published a new scientific article

24/11/2022
PELyon is happy to share its new article: Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis, published in Respiratory Medecine and Research. Great thanks to the co-authors, to the CNAM for the access to SNDS data and to F. Hoffmann-La Roche company…

We have partnered with healthcare professionals in the pharmaceutical and biomedical industry, healthcare facilities, health authorities, and associations since 2010.

 

Our experience and skills help them to respond appropriately to strategic decisions on healthcare products and programmes including quality of care, adherence, drug use, cost of illness studies, and comparison of treatment strategies.

 

We are a multidisciplinary team made up of doctors, project managers, epidemiologists, biostatisticians and data analysts.

Our values

Independence

We work on projects with a public health interest and are committed to publishing the scientific results obtained.

Reliability

We meet deadlines and never compromise on the quality of our deliverables.

Integrity

We draw up our protocols and conduct our analyses according to epidemiological best practice and established procedures.

ÉVALUER
les fardeaux économiques et cliniques des maladies
COMPARER
des stratégies de prise en charge
Publications

Experience

The public health value of the results of the studies carried out by PELyon is evidenced by their publication in international peer-reviewed scientific journals.